Vir Biotechnology (VIR) has priced its initial public offering of 7,142,858 common shares at $20.00/share, for expected gross proceeds of ~$142.9M.
Underwriters over-allotment is an additional 1,071,428 shares.
The shares are expected to begin trading on Nasdaq today.
Net proceeds will be used to complete and advance clinical trials, for working capital and other general corporate purposes.
Closing date is October 16.
https://seekingalpha.com/news/3505190-vir-bio-prices-ipo-20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.